Literature DB >> 27139476

Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.

Melinda M Pettigrew1, Brian T Tsuji2, Janneane F Gent3, Yong Kong4, Patricia N Holden2, Sanjay Sethi5, Timothy F Murphy6.   

Abstract

Little is known about the effect of antibiotics on eradication of carriage and development of resistance in Haemophilus influenzae in individuals with chronic obstructive pulmonary disease (COPD). Our goals were to assess antibiotic susceptibilities, prevalence of resistance genes, and development of resistance in H. influenzae and to evaluate the effect of macrolide and fluoroquinolone administration on H. influenzae eradication. Data were from a 15-year longitudinal study of COPD. Genome sequence data were used to determine genotype and identify resistance genes. MICs of antibiotics were determined by reference broth microdilution. Generalized linear mixed models were used to evaluate associations between antibiotic use and H. influenzae eradication. We examined 267 H. influenzae isolates from 77 individuals. All newly acquired H. influenzae isolates were susceptible to azithromycin. Five of 27 (19%) strains developed 4-fold increases in azithromycin MICs and reached or exceeded the susceptibility breakpoint (≤4 μg/ml) during exposure. H. influenzae isolates were uniformly susceptible to ciprofloxacin, levofloxacin, and moxifloxacin (MIC90s of 0.015, 0.015, and 0.06, respectively); there were no mutations in quinolone resistance-determining regions. Fluoroquinolone administration was associated with increased H. influenzae eradication compared to macrolides (odds ratio [OR], 16.67; 95% confidence interval [CI], 2.67 to 104.09). There was no difference in H. influenzae eradication when comparing macrolide administration to no antibiotic (OR, 1.89; 95% CI, 0.43 to 8.30). Fluoroquinolones are effective in eradicating H. influenzae in individuals with COPD. Macrolides are ineffective in eradicating H. influenzae, and their use in COPD patients may lead to decreased macrolide susceptibility and resistance.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27139476      PMCID: PMC4914697          DOI: 10.1128/AAC.00301-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  Characterization of a clinical isolate of Haemophilus influenzae with a high level of fluoroquinolone resistance.

Authors:  J M Rodríguez-Martínez; L López; I García; A Pascual
Journal:  J Antimicrob Chemother       Date:  2006-01-23       Impact factor: 5.790

Review 2.  Infection in the pathogenesis and course of chronic obstructive pulmonary disease.

Authors:  Sanjay Sethi; Timothy F Murphy
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245

3.  Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over a 3- or 5-day period in healthy subjects.

Authors:  G W Amsden; A N Nafziger; G Foulds
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

4.  Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.

Authors:  T A Davies; L M Kelly; D B Hoellman; L M Ednie; C L Clark; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 5.  Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program.

Authors:  Robert P Rennie; Khalid H Ibrahim
Journal:  Clin Infect Dis       Date:  2005-08-15       Impact factor: 9.079

6.  Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.

Authors:  S Chodosh; A Schreurs; G Siami; H W Barkman; A Anzueto; M Shan; H Moesker; T Stack; S Kowalsky
Journal:  Clin Infect Dis       Date:  1998-10       Impact factor: 9.079

7.  Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Andrew T Schiffmacher; Sanjay Sethi
Journal:  Am J Respir Crit Care Med       Date:  2004-04-29       Impact factor: 21.405

8.  Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial.

Authors:  Sevim Uzun; Remco S Djamin; Jan A J W Kluytmans; Paul G H Mulder; Nils E van't Veer; Anton A M Ermens; Aline J Pelle; Henk C Hoogsteden; Joachim G J V Aerts; Menno M van der Eerden
Journal:  Lancet Respir Med       Date:  2014-04-15       Impact factor: 30.700

9.  Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.

Authors:  Sanjay Sethi; Paul W Jones; Marlize Schmitt Theron; Marc Miravitlles; Ethan Rubinstein; Jadwiga A Wedzicha; Robert Wilson
Journal:  Respir Res       Date:  2010-01-28

Review 10.  Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.

Authors:  Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more
  15 in total

1.  Discovery and Contribution of Nontypeable Haemophilus influenzae NTHI1441 to Human Respiratory Epithelial Cell Invasion.

Authors:  C P Ahearn; C Kirkham; L D Chaves; Y Kong; M M Pettigrew; T F Murphy
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

2.  Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.

Authors:  Brian T Tsuji; James Fisher; Raheal Boadi-Yeboah; Patricia N Holden; Sanjay Sethi; Melinda M Pettigrew; Timothy F Murphy
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 3.  Insights on persistent airway infection by non-typeable Haemophilus influenzae in chronic obstructive pulmonary disease.

Authors:  Christian P Ahearn; Mary C Gallo; Timothy F Murphy
Journal:  Pathog Dis       Date:  2017-06-01       Impact factor: 3.166

4.  A Comparative Study of Chest Computed Tomography Findings: 1030 Cases of Drug-Sensitive Tuberculosis versus 516 Cases of Drug-Resistant Tuberculosis.

Authors:  Nianlan Cheng; Shuo Wu; Xianli Luo; Chunyan Xu; Qin Lou; Jin Zhu; Lu You; Bangguo Li
Journal:  Infect Drug Resist       Date:  2021-03-18       Impact factor: 4.003

5.  Haemophilus influenzae genome evolution during persistence in the human airways in chronic obstructive pulmonary disease.

Authors:  Melinda M Pettigrew; Christian P Ahearn; Janneane F Gent; Yong Kong; Mary C Gallo; James B Munro; Adonis D'Mello; Sanjay Sethi; Hervé Tettelin; Timothy F Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-19       Impact factor: 11.205

6.  Lower Airway Bacterial Colonization Patterns and Species-Specific Interactions in Chronic Obstructive Pulmonary Disease.

Authors:  David M Jacobs; Heather M Ochs-Balcom; Jiwei Zhao; Timothy F Murphy; Sanjay Sethi
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

7.  Microbiological airway colonization in COPD patients with severe emphysema undergoing endoscopic lung volume reduction.

Authors:  Franziska C Trudzinski; Frederik Seiler; Heinrike Wilkens; Carlos Metz; Annegret Kamp; Robert Bals; Barbara Gärtner; Philipp M Lepper; Sören L Becker
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-12-19

8.  Ampicillin resistance in Haemophilus influenzae from COPD patients in the UK.

Authors:  Satyanarayana Maddi; Umme Kolsum; Sarah Jackson; Richard Barraclough; Barbara Maschera; Karen D Simpson; Thierry G Pascal; Serge Durviaux; Edith M Hessel; Dave Singh
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-05-22

9.  Antibiotic de-escalation principle in elderly patients with chronic obstructive pulmonary disease complicated with severe pneumonia.

Authors:  Baohong Xiao; Mei Wang; Xiaoling Hu; Jinfeng Li; Fangfang Wang; Jiaxing Sun
Journal:  Exp Ther Med       Date:  2017-02-21       Impact factor: 2.447

Review 10.  Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults.

Authors:  María-José Giménez; Lorenzo Aguilar; Juan José Granizo
Journal:  Multidiscip Respir Med       Date:  2018-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.